Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Quantum-Si (NASDAQ:QSI) Rocketed After Its Protein Sequencer Reached 19 of 20 Amino Acids

● Proteus can now identify 19 of the 20 amino acids.

Nitish Kishor | 12 October 2026

Recursion (NASDAQ:RXRX): Why It Climbed on the Nasdaq Composite as an NIH Report Swept Biotech

● Recursion Pharmaceuticals climbed solidly on Friday as biotech stocks rallied, with no announcement from the company.

Nitish Kishor | 12 October 2026

ImmunityBio (NASDAQ:IBRX) Stock: Why It Climbed on the Nasdaq Composite as Cancer-Focused Biotechs Rallied

● ImmunityBio climbed on Friday, trading at about $10.60 by mid-morning as cancer-focused biotech stocks rallied.

Nitish Kishor | 12 October 2026

Illumina (NASDAQ:ILMN): Why It Jumped on the S&P 500 as Genomics Tools Rallied With the Biotech Bid

● Illumina jumped on Friday, ranking among the S&P 500's stronger gainers, though no company announcement explained the move.

Nitish Kishor | 12 October 2026

Why Iovance Biotherapeutics (NASDAQ:IOVA) Jumped on the Nasdaq Composite as Cancer-Therapy Names Rallied

● Iovance Biotherapeutics jumped strongly on Friday as cancer-focused drug developers rallied, with no company news of its own.

Nitish Kishor | 12 October 2026

Why Johnson & Johnson (NYSE:JNJ) Gained on the Dow as Health Care Led the Market Before Earnings

● Johnson & Johnson gained on Friday, closing at $261.44 and finishing among the Dow's advancers, with no fresh company news.

Nitish Kishor | 12 October 2026

Merck (NYSE:MRK) Stock: Why It Rose on the Dow as Drugmakers Caught a Bid on a Cancer-Vaccine Report

● Merck had no company-specific announcement and was lifted by a wave of buying across drugmakers and biotech companies.

Nitish Kishor | 12 October 2026

Moderna (NASDAQ:MRNA): Why It Rocketed on the Nasdaq-100 as a Cancer-Vaccine Report Met Its Index Debut

● Moderna rocketed on Friday, closing at $225.00, up $28.00, at the top of its day's range of $197.17 to $225.00.

Nitish Kishor | 12 October 2026

Moderna (NASDAQ:MRNA) Stock Hits Its Highest Level Since 2021 as a Cancer-Vaccine Report Lands

● Moderna climbed $28.00 to $225.00 on Friday, taking the stock to its highest level since 2021, according to market data.

Nitish Kishor | 12 October 2026
Support

Hi! How can we help you today?

Loading…